Background: Diabetic peripheral neuropathy (DPN) is a complication of diabetes that occurs in 40 - 60 million individuals worldwide and is associated with other chronic diseases. However, there are no review studies that present the state-of- the- art and technologies developed to circumvent this important health problem.
Material And Methods: This review was conducted based on scientific papers and patents. The papers were retrieved from Lilacs, PubMed, and Web of Science databases, and the patents from INPI, ESPACENET, WIPO, and GOOGLE PATENTS. Thus, a sample consisting of 14 scientific articles and 667 patents was analyzed.
Results: From the analysis of the data, we drew an overview of the development of biomedical technologies for DPN and detected the pioneering spirit of China, the USA, and Japan in the area, with a focus on the treatment of DPN. Based on this, we carried out a SWOT analysis to help direct future efforts in the area, which should focus primarily on developing technologies for prevention, early diagnosis, and, above all, cure of the disease to reduce the important impact of this disease in various sectors of society.
Conclusion: This study finds a concentration of diabetic peripheral neuropathy products, especially therapeutic drugs, in high-income countries. It highlights the need for global collaboration and strategic focus on therapeutic adherence and preventive strategies to effectively manage DPN.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/0118722083314714240820115610 | DOI Listing |
Background: Diabetic mononeuropathies, which are focal neuropathies, are less common than peripheral neuropathy in diabetes. They are frequently underreported or misdiagnosed due to mild or unnoticed cases. Early detection and treatment are crucial to prevent worsening nerve damage and complications.
View Article and Find Full Text PDFCureus
December 2024
Public Health, Ministry of Health Malaysia, Kuala Lumpur, MYS.
Background: Identifying trends of hospital admissions and costs for cardiovascular disease events (CVDEs) is crucial for public health intervention and the economic burden for future clinical improvements and better outcomes. This study aims to define the admission trends and cost of CVDE among type 2 diabetes mellitus (T2DM) patients in Malaysia between 2014 and 2020. Methodology: An ecological study was conducted using hospital admission data taken from the Casemix database in public hospitals in Malaysia.
View Article and Find Full Text PDFJ Diabetes Metab Disord
June 2025
Department of Biostatistics and Epidemiology, University of Social Welfare and Rehabilitation Science, Tehran, Iran.
Objective: Type 2 diabetes mellitus (T2DM) is a common condition that can lead to adverse macrovascular complications. This study aims to determine the prevalence of macrovascular complications in adults aged ≥ 50 with T2DM in Ardakan city, using data from the Ardakan Cohort Study on Aging (ACSA).
Methods: A cross-sectional investigation involved 5933 participants from the ACSA; of those assessed, 2340 had T2DM.
J Med Ultrasound
November 2024
[This corrects the article on p. 275 in vol. 32, PMID: 39310878.
View Article and Find Full Text PDFCirc Cardiovasc Qual Outcomes
January 2025
Division of Cardiology Lifespan Cardiovascular Institute, Warren Alpert Medical School of Brown University, Providence, RI (J.D.A.).
Background: In-hospital mortality risk prediction is an important tool for benchmarking quality and patient prognostication. Given changes in patient characteristics and treatments over time, a contemporary risk model for patients with acute myocardial infarction (MI) is needed.
Methods: Data from 313 825 acute MI hospitalizations between January 2019 and December 2020 for adults aged ≥18 years at 784 sites in the National Cardiovascular Data Registry Chest Pain-MI Registry were used to develop a risk-standardized model to predict in-hospital mortality.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!